Fexofenadine shortage — NL supply status & alternatives

Fexofenadine

ATC R06AX26

🇦🇺 AUST R 342454 · Sanofi-Aventis Healthcare Pty Ltd T/A Sanofi Consumer Healthcare

In supply · Australia

Fexofenadina CiplaTopcare Allergy Relief

In supply · 🇦🇺 Australia · short in🇳🇱 NL

In supply in Australia

Reading today’s signals…

🇦🇺 AUAEMPA$13.66DPMQ A$57.12details →

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Brand names	Fexofenadina Cipla, Topcare Allergy Relief

ATC level 5	R06AX26

ATC level 4	R06AX

Therapeutic category	Auto-created by CBG-MEB (Netherlands) scraper

Controlled substance	No

Marketing-authorisation holders	Sanofi-Aventis Healthcare Pty Ltd T/A Sanofi Consumer Healthcare, Nova Pharmaceuticals Australasia Pty Ltd, Cipla Australia Pty Ltd, Generics (UK) Limited +1 more

Registrations on file	19

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 PBS · July 2026

🇦🇺 AU

● Official price on file

Ex-manufacturer

A$13.66

AEMP

Dispensed (DPMQ)

A$57.12

incl. fees

Pack

fexofenadine hydrochloride 60 mg tablet, 20

Source: PBSEffective July 2026 · AUD

Other markets

🇬🇧 GB

£1.14

Drug Tariff

🇺🇸 US

US$0.16

Acquisition

🇫🇷 FR

€2.24

Retail price

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

1 API manufacturer

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Very high concentration risk

Virupaksha Organics LTD

Manufacturing countries: India · Source: FDA List of Drug Master Files

Shortage status by regulator official notices

🇳🇱

Netherlands

CBG-MEB · 2d ago

Medium

Verified timeline regulator events

🇳🇱 3 July 2026

medium reported

🇳🇱 30 June 2026

medium reported

🇳🇱 19 June 2026

medium reported

🇳🇱 15 June 2026

medium reported

🇳🇱 9 June 2026

medium reported

🇳🇱 3 June 2026

medium reported

Sources official regulators

🇳🇱

CBG-MEB

verified 2d ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders19 registrations · 5 MA holders

Product	Strength	Form	Market	MA holder	Status
TELFAST fexofenadine hydrochloride	180 mg	—	🇦🇺 AU	Sanofi-Aventis Healthcare Pty Ltd T/A Sanofi Consumer Healthcare	Active
Fexodin	180 mg	—	🇦🇺 AU	Nova Pharmaceuticals Australasia Pty Ltd	Active
AVALLON FEXOFENADINE HAYFEVER ALLERGY RELIEF fexofenadine hydrochloride	60 mg	—	🇦🇺 AU	—	Active
AVALLON FEXOFENADINE HAYFEVER ALLERGY RELIEF fexofenadine hydrochloride	120 mg	—	🇦🇺 AU	—	Active
AVALLON FEXOFENADINE HAYFEVER AND ALLERGY RELIEF fexofenadine hydrochloride	180 mg	—	🇦🇺 AU	—	Active
Chemist'S Own Fexo	180mg	—	🇦🇺 AU	—	Active
Chemist'S Own Fexo	120mg	tabfc	🇦🇺 AU	—	Active
TERRYWHITE CHEMMART FEXOFENADINE HAYFEVER & ALLERGY RELIEF fexofenadine hydrochloride	180 mg	—	🇦🇺 AU	Cipla Australia Pty Ltd	Active
PRICELINE PHARMACY FEXOFENADINE HAYFEVER & ALLERGY RELIEF fexofenadine hydrochloride	180 mg	—	🇦🇺 AU	Cipla Australia Pty Ltd	Active
PHARMACY HEALTH FEXOFENADINE HAYFEVER & ALLERGY RELIEF fexofenadine hydrochloride	180 mg	—	🇦🇺 AU	Cipla Australia Pty Ltd	Active
TELFAST ORAL LIQUID fexofenadine hydrochloride	6mg	—	🇦🇺 AU	Sanofi-Aventis Healthcare Pty Ltd T/A Sanofi Consumer Healthcare	Active
Coles Hayfever Allergy Relief Fexofenadine Hydrochloride	180mg	—	🇦🇺 AU	Nova Pharmaceuticals Australasia Pty Ltd	Active
Fexofenadine Hydrochloride	120 MG	tablet	🇬🇧 GB	Generics (UK) Limited	Active
Fexofenadine Hydrochloride	180 MG	tablet	🇬🇧 GB	Generics (UK) Limited	Active
Fexofenadine Hydrochloride	120MG	tablet	🇬🇧 GB	DR REDDY'S LABORATORIES (UK) LIMITED	Active

+4 more registrations on file

Mederti Drug Report

Generated 7 July 2026 · Australia market · 1 regulatory source

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.